Adamas Pharmaceuticals Stock Price - ADMS

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Adamas Pharmaceuticals Inc ADMS NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.01 -0.18% 5.59 5.56 5.75 5.62 5.60 20:00:00
Bid Price Ask Price Spread Spread % News
5.35 6.05 0.70 11.57% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,491 314,819 $ 5.64 $ 1,775,723 467,511 3.35 - 12.57
Last Trade Time Type Quantity Stock Price Currency
16:16:35 priorref 600 $ 5.59 USD

Adamas Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 155.72M 27.86M $ -131.00M -4.88 - 26.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 2.00 3.20%

more financials information »

Adamas Pharmaceuticals News

Loading Messages....

Latest ADMS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADMS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week5.676.155.4755.74286,825-0.08-1.41%
1 Month6.026.154.955.57243,553-0.43-7.14%
3 Months5.527.453.474.94655,5590.071.27%
6 Months6.507.783.355.16586,045-0.91-14.0%
1 Year10.6912.573.355.89520,284-5.10-47.71%
3 Years17.4444.003.3518.39608,909-11.85-67.95%
5 Years17.4044.003.3518.49447,478-11.81-67.87%

Adamas Pharmaceuticals Description

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

Your Recent History
Adamas Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.